Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31271389 | 0.87 | GPR119 (0.59) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL25310135 | 0.87 | GPR119 (0.59) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL25309533 | 0.87 | GPR119 (0.59) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL31271385 | 0.86 | GPR119 (0.58) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL3579478 | 0.85 | GPR119 (0.59) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL24962970 | 0.85 | GPR119 (0.57) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL25309058 | 0.84 | GPR119 (0.62) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL25311695 | 0.84 | GPR119 (0.56) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL25313293 | 0.84 | GPR119 (0.56) | GPR119HDAC1CHRM2CHRM1CHRM3 | |
| SCHEMBL20456823 | 0.84 | HDAC1 (0.62) | GPR119HDAC1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-110536889-B | HIV inhibitor compounds | 吉利德科学公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115093421-A | HIV inhibitor compounds | 吉利德科学公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11078208-B1 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3577110-B1 | 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS | GILEAD SCIENCES INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-11078208-B1 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-10752636-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | HASPIN, NFATC1, NHERF1 | GPR119 2006/4885HDAC1 74/4885CHRM2 4853/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | GPR119 3532/4885HDAC1 689/4885CHRM2 4540/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
| US-10294234-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885HDAC1 30/4885CHRM2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.